Your browser doesn't support javascript.
loading
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.
Gao, Shan; Bajrami, Ilirjana; Verrill, Clare; Kigozi, Asha; Ouaret, Djamila; Aleksic, Tamara; Asher, Ruth; Han, Cheng; Allen, Paul; Bailey, Deborah; Feller, Stephan; Kashima, Takeshi; Athanasou, Nicholas; Blay, Jean-Yves; Schmitz, Sandra; Machiels, Jean-Pascal; Upile, Nav; Jones, Terry M; Thalmann, George; Ashraf, Shazad Q; Wilding, Jennifer L; Bodmer, Walter F; Middleton, Mark R; Ashworth, Alan; Lord, Christopher J; Macaulay, Valentine M.
Afiliación
  • Gao S; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Bajrami I; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Verrill C; Department of Cellular Pathology and NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, United Kingdom.
  • Kigozi A; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Ouaret D; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Aleksic T; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Asher R; Department of Cellular Pathology and NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, United Kingdom.
  • Han C; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Allen P; Department of Cellular Pathology, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, United Kingdom.
  • Bailey D; Department of Cellular Pathology, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, United Kingdom.
  • Feller S; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Kashima T; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Athanasou N; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, Department of Pathology, Nuffield Orthopaedic Centre, Oxford, United Kingdom.
  • Blay JY; University Claude Bernard Lyon I, Centre Léon Bérard, Department of Medicine, Lyon, France.
  • Schmitz S; Service d'oncologie médicale, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
  • Machiels JP; Service d'oncologie médicale, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
  • Upile N; Liverpool CR-UK Centre, Department of Molecular and Clinical Cancer Medicine, Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Jones TM; Liverpool CR-UK Centre, Department of Molecular and Clinical Cancer Medicine, Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Thalmann G; Department of Urology, Inselspital, Bern, Bern, Switzerland.
  • Ashraf SQ; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Wilding JL; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Bodmer WF; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
  • Middleton MR; Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, Liverpool, United Kingdom.
  • Ashworth A; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Lord CJ; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Macaulay VM; Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom. Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, Liverpool, United Kingdom. valentine.macaulay@oncology.o
Cancer Res ; 74(20): 5866-77, 2014 Oct 15.
Article en En | MEDLINE | ID: mdl-25168481
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fosfoproteínas / Factor I del Crecimiento Similar a la Insulina / Receptor IGF Tipo 1 / Proteínas ras / Resistencia a Antineoplásicos / Proteínas Adaptadoras Transductoras de Señales Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Cancer Res Año: 2014 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fosfoproteínas / Factor I del Crecimiento Similar a la Insulina / Receptor IGF Tipo 1 / Proteínas ras / Resistencia a Antineoplásicos / Proteínas Adaptadoras Transductoras de Señales Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Cancer Res Año: 2014 Tipo del documento: Article País de afiliación: Reino Unido